Taysha Gene Therapies Inc (TSHA) concluded trading on Thursday at a closing price of $1.58, with 4.12 million shares of worth about $6.52 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -31.00% during that period and on January 16, 2025 the price saw a loss of about -3.07%. Currently the company’s common shares owned by public are about 204.94M shares, out of which, 153.61M shares are available for trading.
Stock saw a price change of -18.13% in past 5 days and over the past one month there was a price change of -23.67%. Year-to-date (YTD), TSHA shares are showing a performance of -8.67% which increased to 3.27% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.19 but also hit the highest price of $4.32 during that period. The average intraday trading volume for Taysha Gene Therapies Inc shares is 4.46 million. The stock is currently trading -12.71% below its 20-day simple moving average (SMA20), while that difference is down -23.76% for SMA50 and it goes to -32.99% lower than SMA200.
Taysha Gene Therapies Inc (NASDAQ: TSHA) currently have 204.94M outstanding shares and institutions hold larger chunk of about 69.39% of that.
The stock has a current market capitalization of $323.81M and its 3Y-monthly beta is at 0.92. It has posted earnings per share of -$0.03 in the same period. It has Quick Ratio of 5.51 while making debt-to-equity ratio of 0.70. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for TSHA, volatility over the week remained 9.62% while standing at 8.90% over the month.
Stock’s fiscal year EPS is expected to rise by 61.44% while it is estimated to decrease by -1.39% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by BMO Capital Markets on June 27, 2024 offering an Outperform rating for the stock and assigned a target price of $5 to it. Coverage by Piper Sandler stated Taysha Gene Therapies Inc (TSHA) stock as an Overweight in their note to investors on April 09, 2024, suggesting a price target of $9 for the stock. On February 01, 2023, Jefferies Downgrade their recommendations, while on January 27, 2023, Morgan Stanley Downgrade their ratings for the stock with a price target of $3. Stock get a Neutral rating from Goldman on November 09, 2022.
